Document is current
Any future updates will be listed below
-
Authors
Abichabki, N.
Gaspar, G. G.
Bortolato, L. R.
Lima, D. A. F. S.
Silva, L. N.
Pocente, R. H. C.
Ferreira, J. C.
Ogasawara, T. C.
Pereira, D.
Guerra, R. R.
Wilhelm, C.
Barth, P.
Martins, A. F.
Barth, A.
Braga, G. U. L.
De Martinis, E. C. P.
Bengtsson-Palme, J.
Bellissimo-Rodrigues, F.
Bollela, V. R.
Darini, A. L. C.
Andrade, L. N.
-
Funding
Funding for this research was provided by:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (88887.670254/2022-0 (PROEX))
Conselho Nacional de Desenvolvimento Científico e Tecnológico (140875/2024-7, CNPq– Projeto Universal 406192/2023-5)
Instituto Nacional de Pesquisa em Resistência Antimicrobiana (INCT– MCTI/CNPq/CAPES/FAPs nº 16/2014)
Vetenskapsrådet (2020-00120)
Knut och Alice Wallenbergs Stiftelse (KAW 2020.0239)
Stiftelsen för Strategisk Forskning (FFL21-0174)
Fundação de Amparo à Pesquisa do Estado de São Paulo
- License Information
-
More Information
Article History
Received: 25 September 2024
Accepted: 25 November 2024
First Online: 30 November 2024
Declarations
:
: This study was approved by the Ethics Committee of the Ribeirao Preto School of Pharmaceutical Sciences– University of São Paulo (CAAE: 57488422.0.0000.5403– Protocol CEP/FCFRP nº 5.443.849) and by the Ethics Committee of the University Hospital, Ribeirão Preto Medical School– University of São Paulo (CAAE: 57488422.0.3001.5440– Protocol CEP/HCFMRP n° 5.462.049).
: The authors declare no competing interests.
